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Glutathione (GSH) is the main non-protein thiol in cells whose functions are dependent
on the redox-active thiol of its cysteine moiety that serves as a cofactor for a number
of antioxidant and detoxifying enzymes. While synthesized exclusively in the cytosol
from its constituent amino acids, GSH is distributed in different compartments, including
mitochondria where its concentration in the matrix equals that of the cytosol. This feature
and its negative charge at physiological pH imply the existence of speciﬁc carriers to
import GSH from the cytosol to the mitochondrial matrix, where it plays a key role in
defense against respiration-induced reactive oxygen species and in the detoxiﬁcation of
lipid hydroperoxides and electrophiles. Moreover, as mitochondria play a central strategic
role in the activation andmode of cell death, mitochondrial GSH has been shown to critically
regulate the level of sensitization to secondary hits that induce mitochondrial membrane
permeabilization and release of proteins conﬁned in the intermembrane space that once
in the cytosol engage the molecular machinery of cell death. In this review, we summarize
recent data on the regulation of mitochondrial GSH and its role in cell death and prevalent
human diseases, such as cancer, fatty liver disease, and Alzheimer’s disease.
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INTRODUCTION
Glutathione (GSH), the major intracellular thiol compound, is a
ubiquitous tripeptide produced by most mammalian cells and it is
the main mechanism of antioxidant defense against reactive oxy-
gen species (ROS) and electrophiles. GSH (γ-glutamyl-cysteinyl-
glycine) is synthesized de novo in two sequential enzymatic
ATP-dependent reactions. In the ﬁrst step, cysteine and gluta-
mate are linked in a reaction catalyzed by the γ-glutamylcysteine
synthase (γ-GCS) to form γ-glutamylcysteine. This ﬁrst reaction
is the rate-limiting step in the synthesis of GSH and is regulated
by cysteine availability. The completion of GSH synthesis is cat-
alyzed by glutathione synthetase (GS), in a reaction in which
γ-glutamyl-cysteine is covalently linked to glycine (Figure 1).
The antioxidant function of GSH is determined by the redox-
active thiol (-SH) of cysteine that becomes oxidized when GSH
reduces target molecules (Pompella et al., 2003). Upon reaction
with ROS or electrophiles, GSH becomes oxidized to GSSG,which
can be reduced to GSH by the GSSG reductase (GR). Thus, the
GSH/GSSG ratio reﬂects the oxidative state and can interact with
redox couples to maintain appropriate redox balance in the cell.
Abbreviations: AD, Alzheimer disease; APP, amyloid precursor protein; ASH,
alcoholic steatohepatitis; ETC, electron transport chain; Gpx, glutathione per-
oxidase; Grx, glutaredoxin; GSH, glutathione; GSSG, oxidized glutathione; GST,
glutathione-S-transferase; IMM, inner mitochondrial membrane; mGSH, mito-
chondrial glutathione; MPT, mitochondrial permeability transition; NASH, non-
alcoholic steatohepatitis; NO, nitric oxide; NPC, Niemann–Pick type C disease;
OMM, outer mitochondrial membrane; OXPHOS, oxidative phosphorylation; Prx,
peroxiredoxin; ROS, reactive oxygen species; SOD, superoxide dismutase; StARD1,
steroidogenic acute regulatory domain 1; Trx, thioredoxin.
The synthesis of GSH from its constituent amino acids
occurs exclusively in cytosol, where γ-GCS and GS reside.
However, GSH is found in intracellular organelles including
endoplasmic reticulum (ER), nucleus, and mitochondria to
control compartment-speciﬁc needs and functions (Mari et al.,
2009, 2010). Except for the ER, intracellular GSH is mainly
found in its reduced form. While the percentage of the total
cell GSH content found in mitochondria is minor (10–15%),
the mitochondrial glutathione (mGSH) concentration is simi-
lar to that found in the cytosol. As GSH has a net negative
charge at physiological pH, the high concentration of mGSH
implies the existence of speciﬁc transport systems that work
against an electrochemical gradient (Grifﬁth and Meister, 1985;
Garcia-Ruiz et al., 1994; Mari et al., 2009, 2010). As discussed
below, despite being a small fraction of total intracellular GSH,
mGSH plays a critical function in the maintenance of mito-
chondrial function and cell survival (Lash, 2006; Mari et al.,
2013).
Mitochondria in mammalian cells generate most of the cellular
energy by means of the oxidative phosphorylation (OXPHOS)
that is essential for myriad cellular functions. OXPHOS pro-
vides an efﬁcient mechanism to couple electron transport to
synthesize ATP from ADP. Mitochondria are also involved in
key cellular functions such as Ca2+ homeostasis, heme biosyn-
thesis, nutrient metabolism (Cheng and Ristow, 2013), steroid
hormone biosynthesis, removal of ammonia, integration of
metabolic and signaling pathways for cell death and autophagy
(Hammerman et al., 2004; Renault and Chipuk, 2013). Emerging
evidence indicates a central role of mitochondria in initiating
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FIGURE 1 | Glutathione synthesis in cytosol and compartimentalization
in mitochondria. GSH is synthesized from its constituent amino acids in the
cytosol by the sequential action of γ-glutamylcysteine synthase (γ-GCS) and
GSH synthase (GS). The functions of GSH are determined largely by the –SH
of cysteine as by its role as a cofactor for antioxidant enzymes. Once
synthesized in the cytosol, GSH can be transported to mitochondrial matrix by
different carriers, particularly the 2-oxoglutarate carrier (OGC) and the
dicarboxylate carrier (DIC), located in the mitochondrial inner membrane. The
function the OGC has been shown to be dependent on changes in
mitochondrial membrane dynamics.
signals in response to metabolic and genetic stress which
affects nuclear gene expression, causing changes in cell function
(Raimundo, 2014). Mitochondria contain multiple copies of their
own genome, mitochondrial DNA (mtDNA), which encodes for
13 polypeptides of the OXPHOS and respiratory chain, as well as
two ribosomal RNAs and 22 transfer RNAs necessary for trans-
lation of polypeptides inside mitochondria. As a consequence,
the main mitochondrial proteome (∼1500 proteins) is encoded
by the nucleus, translated in the cytosol and imported into the
mitochondria through speciﬁc translocator complexes (TIM and
TOM) of the inner mitochondrial membrane (IMM) and outer
mitochondrial membrane (OMM), respectively.
Oxidative phosphorylation is organized in a series of subse-
quent steps involving several redox centers distributed in ﬁve
protein complexes embedded in the IMM (Sun et al., 2013;
Venditti et al., 2013). Complex I obtain the electrons from NADH
(NADH-coenzyme Q oxidoreductase) and complex II (succinate-
coQ oxidoreductase) from succinate. Both these two complexes,
independently of each other, use the lipid soluble carrier located
into the IMM, ubiquinone (coenzyme Q) to form ubiquinol.
From ubiquinol, the electrons pass down the redox gradient
through complex III (coenzyme Q-cytochrome c oxidoreductase)
to cytochrome c, then to complex IV (cytochrome c oxidase) and
to the ﬁnal acceptor, oxygen (O2) to produce water. The fall in
electron potential energy through this electron transport chain
(ETC) is used to pump protons out the mitochondrial matrix to
the intermembrane space (IMS). This proton pumping creates a
proton-motive force consisting of electrical and proton gradients.
This force is used by the ﬁfth protein complex (Complex V, ATP
synthase) to regenerate ATP from ADP. The proton-motive force
created by the ETC is also used for many additional mitochondrial
processes, especially those related with transport across the IMM
(Kulawiak et al., 2013).
Although the primary function of mitochondria is to generate
ATP as an energy molecule required for countless cell functions, a
small fraction of electrons from the ETC are transferred directly to
O2, resulting in the generation of the superoxide anion, which can
give rise to other ROS as well as reactive nitrogen species (RNS).
Mitochondria are the primary intracellular site of oxygen con-
sumption and the major source of ROS, most of them originating
from the ETC. In accordance with this, it has been estimated that
the steady-state concentration of superoxide in the mitochondrial
matrix is 5- to 10- fold higher than in the cytosol (Cadenas and
Davies, 2000). Associated with this constant ﬂow of ROS gener-
ation, mitochondria are also a target for the damaging effects of
oxygen radicals (Fernandez-Checa and Kaplowitz, 2005; Kaelin,
2005; Orrenius et al., 2007).
Although ROS generated under physiological conditions are
not harmful, and likely play a signaling role, toxic or pathological
conditions that lead to an impairment of mitochondrial function
can increase the release of ROS. Mitochondrial ROS are increased
under hypoxia, ischemia/reperfusion injury, chemical stress, drug
treatment, and under many pathophysiological conditions (Srini-
vasan andAvadhani, 2012). Despite thatmitochondria are exposed
to the generation of oxidant species, the existence of an efﬁcient
antioxidant defense system, of which mGSH is a critical com-
ponent, prevents or repairs oxidative damage generated during
normal aerobic metabolism (Mari et al., 2013). In the following
sections, we summarize some of the most important aspects of
mGSH physiology, its role in mitochondrial function and release
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of mitochondrial apoptotic factors and the impact of its depletion
in disease.
MITOCHONDRIAL ROS GENERATION AND DEFENSE
Reactive oxygen species can be generated in several intracel-
lular sites, including cytosol, peroxisomes, plasma membrane,
and ER. However, mitochondrial ETC is the main cellular pro-
cess of ROS generation in most cell types in physiological
circumstances (Venditti et al., 2013). Although normal electron
transport in mitochondria involves four-electron reduction of
O2 to water, partial reduction reactions occur under physi-
ological conditions, causing release of superoxide anion and
hydrogen peroxide (H2O2). Although ROS can be generated
at several sites of the ETC (Figure 2; Brand, 2010; Quin-
lan et al., 2013), complex I and complex III (Venditti et al.,
2013) have been shown to be the most important sources of
mitochondrial superoxide generation, although signiﬁcant pro-
duction of ROS in complex II has recently also been reported
(Quinlan et al., 2012).
The primary ROS produced by the ETC is superoxide, a free
radical with moderate reactivity, whose generation can lead to
more reactive or secondary ROS derivatives. Indeed, superox-
ide can undergo dismutation to H2O2, a mild oxidant that can
be converted to the highly reactive hydroxyl radical in the pres-
ence of transition metals (Fe2+, Cu+) by means of the Fenton
reaction. H2O2 has a longer half-life and can cross membranes
(Cadenas and Davies, 2000), consequently it has been identiﬁed
as a suitable second messenger molecule, in part because of its
reactions with speciﬁc oxidation-prone protein cysteinyl residues
(Sies, 2014), which confers properties to H2O2 as a mitochondrial
signal (Raimundo, 2014).
Reactive oxygen species can attack biomembranes, enzymes,
proteins, and nucleic acids (Venditti et al., 2013). These oxidative
effects can be neutralized by antioxidant systems, engaging in a
delicate balance that determines the fate and impact of ROS in
cells. Although oxidative stress was deﬁned originally as a bal-
ance between oxidants and antioxidants systems, an equilibrium
among antioxidant strategies is needed to avoid the generation of
oxidants and ROS (Mari et al., 2010). For instance, if the activity
of superoxide scavenging by SOD2 exceeds the capacity to remove
the H2O2 generated, this oxidant can cause oxidative damage or
be converted to other ROS.
SUPEROXIDE, HYDROGEN PEROXIDE, AND PEROXYNITRITE
GENERATION
Despite the fact that superoxide can be generated in extramito-
chondrial reactions, in most cell types mitochondria appear as
the main source of superoxide generation. From the several sites
that can generate superoxide in the mitochondrial matrix, only
the superoxide produced at complex III appears to be released
FIGURE 2 | Mitochondrial ROS generation and antioxidant defense
systems. Complex I ﬂavin site (CIF ), Complex I ubiquinone site (CIQ ),
Complex II ﬂavin site (CIIF ), and Complex IIIQo (CIIIQ0) are sites of the ETC
components shown to generate superoxide anion. Other sources of
superoxide can be enzymatic reactions that transfer electrons to the ETC
such as mitochondrial glycerol 3-phosphate dehydrogenase (mGPDH), and
the last step of β-oxidation, electron-trasferring ﬂavoprotein ubiquinone
oxidoreductase (ETFQOR) or dehydrogenases such as pyruvate
dehydrogenase (PDH), 2-oxoglutarate dehydrogenase (OGDH) and
branched-chain 2-oxoacid dehydrogenase (BCKDH). Superoxide generated in
the mitochondrial matrix by these sites is dismutated to hydrogen peroxide by
SOD2. Moreover, in response to stress p66Shc translocates to mitochondria
to directly stimulate hydrogen peroxide generation by transferring electrons to
cytochrome c. Hydrogen peroxide is further inactivated using the reducing
equivalents of NADPH by mGSH/Gpx or Prx3/Trx2 antioxidant systems,
yielding water. Mn-dependent superoxide dismutase 2 (SOD2), GSH
peroxidase (GPX1), GSSG-reductase (GR), peroxiredoxin 3 (PRX3),
thioredoxin-2 (TRX2), thioredoxin reductase (TrxRD).
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both into the matrix and the IMS (Quinlan et al., 2013). This
spatial difference (matrix vs. IMS) may determine whether mito-
chondrial superoxide reaches the cytosol or not. The anionic
nature of superoxide and the fact that it is mostly produced
in the mitochondrial matrix determine that the bulk of antiox-
idant defenses to neutralize superoxide and other ROS reside
in the matrix. The ﬁrst line of defense against superoxide is
the presence of a speciﬁc member of the family of metalloen-
zymes called superoxide dismutases (SODs), MnSOD or SOD2,
speciﬁcally located in the mitochondrial matrix, which catalyzes
the dismutation of superoxide anion into H2O2 as shown in
Figure 2. The dismutation of superoxide can also occur sponta-
neously, but such reaction is 104 times slower than the enzymatic
dismutation by SOD2. The relevance of this enzyme is illus-
trated by the fact that global SOD2 deﬁciency leads to neonatal
death in mice (Huang et al., 1997). Superoxide released into the
IMS can be eliminated by a different SOD isoenzyme (Cu, Zn-
SOD, or SOD1), which is found in the cytoplasm of eukaryotic
cells, or scavenged by cytochrome c plus cytochrome c oxidase
system (Okado-Matsumoto and Fridovich, 2001). It has been
proposed that α-tocopherol can also scavenge superoxide, as sug-
gested by experiments with submitochondrial particles isolated
from mice fed with vitamin-E supplemented diet (Chow et al.,
1999).
Although the dismutation of superoxide by SOD2 is a pre-
dominant source of H2O2, there are other reactions that directly
generate H2O2 in mitochondria. For example, the redox activitiy
of p66Shc within mitochondria has been shown to generate H2O2
in the absence of superoxide through oxidation of cytochrome
c (Giorgio et al., 2005). P66Shc normally resides in the cytosol
where it is involved in signaling from tyrosine kinases to Ras.
However, in response to stress p66Shc translocates to mito-
chondria to contribute to the generation of H2O2. Due to the
lack of unpaired electrons, H2O2 is not a free radical but a
potent oxidant that can oxidize mitochondrial components (pro-
teins, lipids, DNA). Besides being a potential source of more
reactive free radicals via Fenton reaction, physiological gen-
eration of H2O2 fulﬁlls a second messenger role and can be
transported across membranes by aquaporins, a family of pro-
teins that act as peroxiporins (Sies, 2014). The detoxiﬁcation
against H2O2 in mitochondria occurs mainly through the GSH
redox system, including the glutathione peroxidases (Gpxs) and
GSH reductases, as well as the presence of peroxiredoxins (Prxs;
Figure 2) using the reducing equivalents of NADPH. Besides these
antioxidant defenses that ensure H2O2 elimination, aquaporins
have been shown to modulate mitochondrial ROS generation.
In this paradigm, aquaporin 8 silencing, which is speciﬁcally
expressed in IMM, enhances mitochondrial ROS generation and
results in mitochondrial depolarization and cell death (Marchissio
et al., 2012). In addition to these conventional sites of mito-
chondrial ROS generation, it has been recently reported that
the branched-chain 2-oxoacid dehydrogenase (BCKDH) com-
plex in mitochondria can produce superoxide and H2O2 at
higher rates than complex I from mitochondria (Quinlan et al.,
2014).
Peroxynitrite is a potent oxidant that is generated upon the
reaction of superoxide with nitric oxide (NO). Its impact on
inactivation of mitochondrial proteins depends on the level of
generation in mitochondria. While ETC is the source of super-
oxide, the existence of mitochondrial NO synthase (mtNOS)
that provides the NO required to form peroxynitrite is contro-
versial. Although the existence of mtNOS has been described in
mitochondrial fractions from different organs, recent evidence in
rat liver mitochondria has questioned the existence of mtNOS,
minimizing the contribution of in situ NO generation within
mitochondrial to the formation of peroxynitrite (Venkatakrish-
nan et al., 2009). However, since NO is freely diffusible across
membranes, it is possible that the mitochondrial production
of peroxynitrite may derive from extramitochondrial NO dif-
fusing into mitochondria to react with superoxide generated
by ETC.
GLUTATHIONE REDOX CYCLE
Hydrogen peroxide is rapidly reduced to water mostly by Gpx,
which utilizes the reducing equivalents from its substrate GSH. In
this enzymatic reaction, GSH becomes oxidized to GSSG, which
is recycled back to GSH by the NADPH-dependent GSSG reduc-
tase as shown in Figure 2. Since GSSG is not readily exported
out of mitochondria (Olafsdottir and Reed, 1988; Yin et al., 2012),
the activity of GR is an important mechanism to control the level
of GSSG in mitochondria. The uncontrolled generation of GSSG
during oxidative stress can contribute to mitochondrial dysfunc-
tion by glutathionylation of target proteins, as described below.
The supply of NADPH is essential to regenerate GSH and dictates
the rate of H2O2 reduction by Gpx while keeping the reduced
status of mitochondria.
So far, eight isoforms of Gpx have been identiﬁed in humans,
which vary in cellular location and substrate speciﬁcity (Brigelius-
Flohe and Maiorino, 2013). Gpx1 is the major isoform localized
in various cellular compartments, including the mitochon-
drial matrix and IMS (Legault et al., 2000; Mari et al., 2009),
which in the liver account for about one third of the total
Gpx activity (Chance et al., 1979). This selenium-containing
homotetramer protein has substrate speciﬁcity for H2O2 and
has been classically believed to be the major H2O2 reducing
enzyme. It also has been described that γ-glutamylcysteine,
the intermediate of GSH biosynthesis, is able to act as a
Gpx1 cofactor in mitochondrial H2O2 detoxiﬁcation, mim-
icking the physiological properties of GSH (Quintana-Cabrera
et al., 2012). Surprisingly, mice with speciﬁc genetic deletion
of Gpx1 appear phenotypically normal and with normal life
span (Ho et al., 1997), suggesting that there are alternative
compensatory mechanisms for H2O2 scavenging in Gpx1 deﬁ-
ciency. However, another report demonstrated mitochondrial
stress and bioenergetics defects in GPx1 null mice (Esposito
et al., 2000). Besides Gpx1, Gpx4 displays preference for lipid
hydroperoxides (Figure 3), and hence plays a key role in pro-
tecting phospholipids, cholesteryl esters and cardiolipin and
defense against apoptosis and maintenance of ETC and OXPHOS
(Cole-Ezea et al., 2012). In line with this vital role in mito-
chondrial defense, Gpx4 null mice die during early embryonic
development, while Gpx4+/− cells are sensitive to oxidative
stress triggers (Legault et al., 2000; Muller et al., 2007). More-
over, Gpx4 has been shown recently to modulate ferroptotic
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FIGURE 3 | Mitochondrial GSH redox cycle and interaction with other
antioxidant defenses. Detoxiﬁcation of harmful lipid peroxides
(Lipid-OOH) to their corresponding hydroxides (lipid-OH) by glutathione
peroxidase 4 (GPX4) and glutathione-S-transferases (GST). Control of
mitochondrial protein glutathionylation (Prot-S-SG, Prot -SH) by glutaredoxin
(GRX2) and thioredoxin 2 (TRX2).
cancer cell death, a speciﬁc form of cell death characterized by
the production of iron-dependent ROS generation (Yang et al.,
2014). This process involved metabolic dysfunction that results in
increased production of cytosolic and lipid ROS, independently of
mitochondria.
PEROXIREDOXIN–THIOREDOXIN REDOX CYCLE
Peroxiredoxins constitute a family of thiol-speciﬁc peroxidases
that rely on thioredoxins (Trxs) as the hydrogen donor for the
reduction of H2O2 and lipid hydroperoxides (Chae et al., 1999).
Prx3 is the Prx isoform exclusively located in mitochondria, sug-
gesting that it plays a primary line of defense against H2O2
produced by the mitochondrial respiratory chain. Prx3 homod-
imer has a redox-sensitive cysteine that upon reaction with H2O2
is oxidized to Cys-SOH, which then reacts with neighboring Cys-
SH of the other subunit to form an intermolecular disulﬁde
that can be readily reduced by thioredoxin reductase 2 (TrxRD2;
Chang et al., 2004; Orrenius et al., 2007). The fact that the oxida-
tion state of the active site cysteine of Prx can be transferred to
other proteins allows Prx to function as a sensor of H2O2 (Rhee
et al., 2012). Likewise, Prx5, the last identiﬁed member of the
six mammalian Prxs (Knoops et al., 2011), is widely expressed
in tissues but it is not exclusively located in mitochondria. In
human cells, it has been shown that Prx5 can be targeted to mito-
chondria, peroxisomes, cytosol, and nucleus. The targeting of
Prx5 to mitochondria is highly conserved among species (Van der
Eecken et al., 2011), and it has been associated with the protec-
tion of mtDNA from oxidative attacks (Banmeyer et al., 2005).
Prx5 is a peroxidase that can use cytosolic or mitochondrial Trx
to reduce alkyl hydroperoxides or peroxynitrite with high rate
constants, whereas its reaction with H2O2 is modest (Knoops
et al., 2011). Therefore, as opposed to Prx3, Prx5 has been viewed
mainly as a cytoprotective antioxidant enzyme rather than as a
redox sensor and appears to be a unique Prx exhibiting speciﬁc
functional and structural feature (Knoops et al., 2011; Zhu et al.,
2012).
As noted above, Trxs are responsible for reducing Prx back to
their reduced, oxidant-scavenging state, while thioredoxin reduc-
tases (TrxRDs) keep the reduced state of Trxs using NAPDH
reducing equivalents, as depicted in Figure 2. Either Trx and
TrxRD are expressed as isoforms for both predominantly cytosolic
(Trx1 and TrxRD1) or mitochondrial (Trx2 and TrxRD2) local-
ization (Enoksson et al., 2005). There are direct links between the
Trx systemandprotein glutathionylation (Casagrande et al., 2002);
and the direct reduction of mitochondrial glutaredoxin 2 (Grx2)
by TrxR is also of important physiological relevance (Johansson
et al., 2004; Enoksson et al., 2005). However, the reduction of
the intermolecular disulﬁde of Prx is speciﬁc to Trx and cannot
be achieved by GSH or Grx (Chang et al., 2004; Orrenius et al.,
2007).
Due to their high rate constant and high abundance, Prx are
thought to be responsible for scavenging nanomolar concentra-
tions of H2O2 associated with redox signaling, while Gpx are
likely important at higher intracellular concentrations, buffering
high ROS levels to avoid cell damage and stress signaling response
(Sena and Chandel, 2012). In addition there is emerging evidence
indicating that both antioxidant systems (mGSH and Prx3) are
mutually regulated. For instance, depletion of mGSH results in
Trx2 oxidation (Zhang et al., 2007), while hypercholesterolemic
pigs with selective depletion of mGSH in heart mitochondria,
exhibit decreased levels of the mitochondria-speciﬁc antioxidant
enzymes such as SOD2, Trx2, and Prx3 (McCommis et al., 2011).
Collectively, these data highlight a key role of mGSH in maintain-
ing a healthy antioxidant system in both systems and on H2O2
homeostasis.
DEFENSE AGAINST ELECTROPHILES AND PROTEIN
GLUTATHIONYLATION
In addition to the defense against oxidants and ROS, GSH
plays also an important role in the protection against elec-
trophiles by glutathione-S-transferases (GSTs). Electrophiles can
be generated as a consequence of metabolic processes involving
both endogenous compounds and xenobiotics. GSTs exhibit a
wide intracellular distribution, being localized in mitochondria
(GSTA1), cytosol (alpha, mu, pi, and zeta) and membrane-
bound (MGST1) isoforms (Aniya and Imaizumi, 2011; Li et al.,
2011). Mitochondrial GSTs display both GSH transferase and
peroxidase activities that detoxify harmful byproducts through
GSH conjugation or GSH-mediated peroxide reduction (Figure 3;
Hayes et al., 2005; Aniya and Imaizumi, 2011). Among human
mitochondrial GSTs, the isoforms hGSTA4-4, hGSTA1, hGSTA2,
and hGSTP1 showed peroxidase activity, with hGSTA4-4 exhibit-
ing the highest activity (Gardner and Gallagher, 2001; Gallagher
et al., 2006). Moreover, recent studies have shown that GSTA4
expression is selectively downregulated in adipose tissue of obese
insulin-resistant C57BL/6J mice and in human obesity-linked
insulin resistance (Curtis et al., 2010). Mitochondrial function
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in adipocytes of lean or obese GSTA4-null mice was signif-
icantly compromised compared with wild-type controls and
was accompanied by an increase in superoxide anion produc-
tion.
Glutathionylation, a keymechanismof post-translationalmod-
iﬁcation of proteins, involves the formation of a disulﬁde bridge
between GSH and an available protein cysteine thiol. Non-
enzymatic glutathionylation occur mostly during oxidative stress
when GSH/GSSG is ∼1 and levels of ROS are high. This pro-
cess is non-speciﬁc and can lead to the hyper-glutathionylation
of proteins, altering their activity. Enzymatic glutathionylation
reactions are tightly controlled and highly speciﬁc and are con-
sidered a major post-translational modiﬁcation that occurs in
response to ﬂuctuations in local redox environments. The Grx
family of proteins plays a key role in the regulation of glutathiony-
lation reactions (Figure 3; Lillig et al., 2008). Although Grx are
mainly responsible for deglutathionylation reactions, recent evi-
dence has indicated a role for Grx in protein glutathionylation,
mediated by the stabilization of a GSH thiyl radical which is
then subsequently transferred to an available protein thiol (Starke
et al., 2003). In most cases, Grx catalyze the deglutathionyla-
tion of proteins GSH disulﬁde mixtures (PSSGs). Grx exhibit
site-speciﬁc distribution with Grx1 being speciﬁcally located in
cytosol while Grx2 localizes in mitochondria. Both Grx cat-
alyze the deglutathionylation of protein targets in two steps; ﬁrst,
the N-terminal cysteine on Grx deglutathionylates PSSG via a
thiol disulﬁde exchange reaction yielding PSH and a Grx–SSG
intermediate; second, Grx–SSG binds GSH and the glutathionyl
moiety is removed regenerating Grx and producing GSSG. Grx2
has close to 34% homology to Grx1 and was recently identi-
ﬁed as the enzyme required for deglutathionylation reactions in
mitochondria (Gladyshev et al., 2001; Lundberg et al., 2001; Gal-
logly et al., 2009; Stroher and Millar, 2012). The catalytic cycle
of Grx2 is also quite similar to Grx1 except that the Grx2–
SSG intermediate can be reduced by NADPH and TrxRD. It is
also important to point out that unlike Grx1, Grx2 complexes
iron (Fe), which is required to modulate its activity (Johans-
son et al., 2004; Lillig et al., 2005). Interestingly, Grx2 has been
shown catalyze both the deglutathionylation and glutathionyla-
tion of target proteins in mitochondria. The reversible nature of
Grx2 is associated with its sensitivity to changes in GSH/GSSG;
a high GSH/GSSG promotes protein deglutathionylation and a
low GSH/GSSG activates Grx2 glutathionylase activity (Beer et al.,
2004; Hurd et al., 2008). Themain target for Grx2 inmitochondria
is Complex I, although UCP3 and the 2-oxoglutarate dehydro-
genase (OGDH) have been also shown to be deglutathionylated
by Grx2. The role of Grx2 in maintaining mitochondrial func-
tion has been recently shown in heart from Grx2 null mice.
Grx2 deletion decreased ATP production by complex I-linked
substrates (Mailloux et al., 2014). Grx2−/− hearts also devel-
oped left ventricular hypertrophy and ﬁbrosis and mice developed
hypertension.
MITOCHONDRIA AND CELL DEATH
Besides their fundamental role in energy generation,mitochondria
also play a strategic role in the regulation of cell death, includ-
ing apoptosis (caspase-dependent and independent) and necrosis.
Apoptosis describes a programmed mode of cell death that is
characterized by a series of biochemical events that ultimately lead
to cell fragmentation into compact membrane-enclosed struc-
tures, called “apoptotic bodies” that are taken up by neighboring
cells and phagocytes, preventing inﬂammation, and tissue dam-
age (Taylor et al., 2008). Apoptosis is induced via two main routes
involving either the mitochondria (the intrinsic pathway) or the
activation of death receptors (the extrinsic pathway). Both path-
ways are linked in some cell types by the cleavage of BID, a
proapoptotic member of the Bcl-2 family of proteins, generat-
ing tBID in a process catalyzed by caspase-8 activated by the
extrinsic pathways (Scafﬁdi et al., 1998). The intrinsic pathway
of apoptosis is activated by stimuli that lead to the permeabiliza-
tion of the OMM and the subsequent release of proteins from
the mitochondrial IMS, such as cytochrome c (Martinou and
Green, 2001; Kroemer et al., 2007). Cytochrome c normally resides
within the cristae of the IMM and is sequestered by narrow cristae
junctions. As mentioned above, within the IMM, cytochrome c
participates in the mitochondrial ETC, using its heme group as a
redox intermediate to shuttle electrons between complex III and
complex IV. However, when the cell detects an apoptotic stimulus,
such as DNA damage or metabolic stress, the intrinsic apoptotic
pathway is triggered and mitochondrial cytochrome c is released
into the cytosol (Kroemer et al., 2007). This process is thought
to occur in two phases, ﬁrst the mobilization of cytochrome c
and then its translocation through permeabilized OMM. In addi-
tion to cytochrome c, other IMS proteins are also mobilized
and released into the cytosol where they promote or counteract
caspase activation and hence cell death (Li et al., 2001; Munoz-
Pinedo et al., 2006). For instance, the release of Smac/Diablo into
the cytosol ensures the efﬁciency of caspase 3 in proteolyzing
target proteins through inhibition of inhibitor of apoptosis pro-
teins (IAPs). Moreover, other specialized mitochondria-residing
proteins, such as the apoptosis inducing factor (AIF) and endonu-
clease G, are translocated to the nuclei following their release from
mitochondria and promote peripheral chromatin condensation
and high molecular weight DNA fragmentation. While the above
evidence indicates that the mitochondrial apoptotic pathway pro-
motes cell death, recent provocative evidence has shown that the
intrinsic apoptosis pathway mediates the pro-longevity response
to mitochondrial ROS in Caenorhabditis elegans by triggering a
unique pattern of gene expression that modulates stress sensitiv-
ity and promotes survival (Yee et al., 2014). Whether this newly
described pathway has implication in mammals needs further
veriﬁcation.
MITOCHONDRIAL MEMBRANE PERMEABILIZATION AND RELEASE OF
PROAPOPTOTIC PROTEINS
While mitochondrial proteins are normally secured in the IMS,
understanding the mechanism of release may be of relevance to
control cell death. The rupture of the physical barrier (OMM)
that limits their release into the cytosol constitutes a point-of-no-
return in cell death (Martinou and Green, 2001; Kroemer et al.,
2007). Current evidence supports the existence of two compatible
mechanisms leading to the breakage of OMM: the mitochon-
drial permeability transition (MPT), and the permeabilization of
OMM without disruption of the inner membrane. The former
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is a process characterized by mitochondrial swelling, IMM per-
meabilization and OMM rupture as a secondary event. On the
other hand, there is evidence indicating the selective permeabi-
lization of OMM in the absence of disrupted inner membrane.
The relative prevalence of these pathways in the regulation of
cell death is not deﬁnitively established. One important feature
of mitochondrial permeabilization is the loss of function result-
ing in the inability of mitochondria to synthesize ATP through
the OXPHOS. However, while the ﬁnal outcome of mitochon-
drial dysfunction is cell death, the phenotype of death (apoptosis
and/or necrosis) depends on the level of cellular ATP, as ATP is
required for the efﬁcient assembly of the apoptosome. Alterna-
tively to MPT in the control of OMM permeabilization, Bcl-2
family members are also known to play a major function. Bcl2-
family death agonists induce OMM permeabilization, thereby
promoting cytochrome c release, whereas Bcl2-family death antag-
onists prevent it. Thus, Bcl2-family proteins controlmitochondrial
integrity, regulate cytochrome c release and intrinsic apoptosis
(Youle and Strasser, 2008). Under non-apoptotic conditions, Bax
is inactive and present in the cytosol as a monomer. Following
an apoptotic stimulus, Bax is activated and translocates to the
mitochondria, where it undergoes a conformational change and
inserts into the OMM. Bax oligomerization is associated with
the formation of openings in the OMM to allow the release
of cytochrome c and other IMS proteins into the cytosol, and
hence Bax oligomerization is considered a critical regulatory
point in cell death (Youle and Strasser, 2008). Further under-
standing themechanisms underlyingOMMpermeabilizationmay
provide novel strategies to regulate cytochrome c and control
apoptosis.
REGULATION OF CELL DEATH BY mGSH
As opposed to apoptosis, necrosis is a morphologically distinct
form of cell death responsible for irreversible tissue destruction
due to bioenergetic failure and oxidative damage. The fun-
damental difference relative to apoptosis is the rapid loss of
cellular membrane potentials due to energy depletion and ion
pump/channel failures, leading to swelling, rupture, and cytol-
ysis. MPT is a regulated non-selective water and solute-passing
protein complex whose molecular characterization remains elu-
sive. Available evidence suggests a role for voltage-dependent
anion channel (VDAC), located in the OMM, and adenine
nucleotide translocase (ANT) across the IMM (Kroemer et al.,
2007; Baines, 2010) and the translocator protein TSPO [previously
called peripheral benzodiazepine receptor (PBR)] as compo-
nents of MPT. However, liver mitochondria from mice lacking
ANT1 and ANT2 can still undergo Ca2+-induced swelling and
MPT, although at a higher threshold, which has been inter-
preted as evidence against a role for ANT in MPT (Kokoszka
et al., 2004). However, recent evidence has demonstrated that
TSPO is dispensable for MPT (Sileikyte et al., 2014). In particu-
lar, heart mitochondria from mice with selective TSPO deletion in
hearts undergo MPT and are as sensitive to ischemia–reperfusion
injury as hearts from control mice. In contrast, the prolyl iso-
merase cyclophilin D in the mitochondrial matrix is an essential
regulator of MPT and the only genetically proven indispens-
able MPT component (Baines et al., 2005; Basso et al., 2005;
Nakagawa et al., 2005; Schinzel et al., 2005). Upon oxidative
stress, sudden MPT causes massive ion inﬂux that dissipates
mitochondrial membrane potential and shuts down OXPHOS,
ATP production and ROS overgeneration. Concomitantly, water
inﬂux causes matrix swelling, rupture of the rigid OMM and
release of apoptogenic proteins sequestered in IMS although,
apoptotic cell death under MPT is inhibited due to energetic fail-
ure and ATP exhaustion and oxidative stress-mediated caspase
inactivation.
A critical step in mitochondrial apoptosis is the mobilization
of cytochrome c from IMS. It has been proposed that during
mobilization cytochrome c detaches from the IMM and disso-
ciates from the membrane phospholipid cardiolipin. A signiﬁcant
proportion of the cytochrome c in the mitochondria seems to be
associated with cardiolipin, involving two major mechanisms. At
physiological pH, cytochrome c has a net positive charge (+8),
establishing an electrostatic bond with the anionic cardiolipin
(Gonzalvez and Gottlieb, 2007). In addition, cytochrome c has
a hydrophobic channel through which one of the four-acyl chains
of cardiolipin inserts. The other chains of cardiolipin remain in
the membrane, thereby anchoring cytochrome c to the IMM.
One mechanism that contributes to cytochrome c detachment
from IMM involves cardiolipin oxidation because oxidized car-
diolipin has a much lower afﬁnity for cytochrome c than the
reduced form. Cardiolipin can be oxidized by ROS or by the
cardiolipin–cytochrome c complex (Kagan et al., 2005). Detach-
ment of cytochrome c from cardiolipin might also be triggered by
increased cytosolic calcium, which weakens the electrostatic inter-
actionbetween cytochrome c and cardiolipin and further generates
ROS via MPT.
In addition, it has been described that oxidized cardiolipin
modulates the biophysical properties of OMM to allow oligomer-
ized Bax to insert and permeabilize the OMM (Mari et al., 2008;
Montero et al., 2010; Landeta et al., 2011). Since mitochondrial
ROS contribute to cardiolipin oxidation and are controlled by
antioxidants (Mari et al., 2008, 2009), mGSH arises as an impor-
tantmodulator of apoptotic cell death by indirectly controlling the
redox state of cardiolipin (Mari et al., 2008; Montero et al., 2010).
mGSH not only regulates cell death susceptibility but the outcome
of cell death (necrosis or apoptosis). Thiol redox status regulate
MPT and enhanced ROS generation can target critical cysteine
residues in cyclophilin D, implying that mGSH depletion would
favor MPT via redox pathways targeting MPT components. In
addition, through modulation of cardiolipin redox state, mGSH
can also regulate OMM permeabilization via MPT and the release
of apoptogenic proteins.
GLUTATHIONE IMPORT TO MITOCHONDRIA
As indicated above, despite the fact that the concentration of
mGSH is high, GSH is not synthesized de novo in the mitochon-
drial matrix, as this organelle lacks the enzymes required for GSH
synthesis. Furthermore, GSH has an overall negative charge at
physiological pH and mitochondria exhibit a large negative mem-
brane potential. Moreover, although GSH can cross OMM, its
transport into mitochondrial matrix cannot be explained by sim-
ple diffusion. Therefore,mGSHarises from the cytosol GSHby the
activity of speciﬁc carriers (Figure 1; Grifﬁth and Meister, 1985).
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Accordingly, recent ﬁndings using dynamic oxidant recovery
assays and GSH-speciﬁc ﬂuorescent reporters, established that
free communication of GSH pools exists between cytosol and
IMS. In contrast, no appreciable communication was observed
between the GSH of the IMS and matrix (Kojer et al., 2012).
Based on substrate speciﬁcity, potential candidates to transport
GSH into mitochondria have been identiﬁed, including the 2-
oxoglutarate carrier (OGC; SLC25A11) and the dicarboxylate
carrier (DIC; SLC25A10; Chen and Lash, 1998; Chen et al., 2000;
Coll et al., 2003; Wilkins et al., 2012), mainly in kidney and liver,
and tricarboxylate carrier (TTC, SLC25A1) in brain mitochon-
dria and astrocytes (Wadey et al., 2009). OGC imports cytosolic
GSH into mitochondria in exchange for 2-oxoglutarate (2-OG)
and other dicarboxylates. Instead, DIC mediates electro-neutral
exchange of dicarboxylates or GSH for inorganic phosphate (Mari
et al., 2009). The relative contribution of each system is differ-
ent depending on the cell type, as discussed in the following
section.
TISSUE-SPECIFIC FEATURES OF GLUTATHIONE IMPORT TO
MITOCHONDRIA
Previous studies in a renal proximal tubular cell line, NRK-
52E, indicated that overexpression of OGC and DIC increased
mGSH levels and protected against oxidant-mediated cell death
(Lash et al., 2002; Xu et al., 2006). Similar ﬁndings were recently
reported in primary renal proximal tubular cells from uninephro-
tectomized rats (Benipal and Lash, 2013). The ﬁndings with DIC
overexpression in kidney cells indicated a role for this carrier in
the mitochondrial transport of GSH in exchange with inorganic
phosphate. In contrast to kidney, no clear evidence for DIC in
the transport of mitochondrial GSH was found in rat liver (Coll
et al., 2003). The functional expression in Xenopus laevis oocytes
microinjected with the DIC cRNA from rat liver did not result in
signiﬁcant GSH transport activity (Coll et al., 2003). Moreover, in
contrast to rat kidney mitochondria, the import of GSH in rat
liver mitochondria showed both a high afﬁnity and low afﬁnity
transport component (Martensson et al., 1990). Likewise, kinetic
analyses of 2-oxoglutarate transport in rat livermitochondria indi-
cated the presence of a single Michaelis–Menten component with
kinetic parameters in the range of those reported previously for
kidney mitochondria (Chen et al., 2000; Coll et al., 2003). These
ﬁndings suggest that the OGC accounts for the low-afﬁnity high
capacity of GSH transport in liver mitochondria, and imply that
the nature of the high afﬁnity GSH transporter remains to be
identiﬁed. Also, OGC and DIC together accounted for only an
apparent 45–50% of the total GSH uptake in liver mitochondria,
in contrast to 70–80% described in kidney mitochondria (Zhong
et al., 2008).
Interestingly, it has been suggested that Bcl-2 participates as
a regulator of mGSH transport by modulating the afﬁnity of
OGC for GSH (Wilkins et al., 2012). Bcl-2 and OGC appear to
act in a coordinated manner to increase the mGSH pool and
to enhance the resistance of neurons to mitochondrial oxidative
stress. In line with this outcome, stable motoneuron-like cell lines
overexpressing OGC displayed an increased expression of Bcl-
2 protein, an effect that was dependent on the mGSH increase.
Conversely, a knockdown of Bcl-2 provoked a decrease in mGSH
and a concomitant oxidative stress sensitization (Wilkins et al.,
2014). Therefore, the antioxidant-like and antiapoptotic function
attributed to Bcl-2 could, at least in part, depend on its potential
to regulate the mGSH transport and status.
In brain, the properties of GSH transport in isolated rat brain
mitochondria seemed to be different from those reported pre-
viously for kidney mitochondria, as they were inﬂuenced most
by inhibitors of the tricarboxylate carrier, citrate, isocitrate, and
benzenyl-1,2,3-tricarboxylate (Wadey et al., 2009). Moreover, in
mouse brain mitochondria another study showed that OGC and
DIC are both expressed in cortical neurons and astrocytes (Kamga
et al., 2010). In addition, butylmalonate, an inhibitor of DIC, sig-
niﬁcantly decreased mGSH, suggesting DIC as the major GSH
transporter inmouse cerebral corticalmitochondria (Kamga et al.,
2010). It has been shown that pharmacological inhibition or
knockdown of a single mGSH transporter signiﬁcantly sensitized
neurons to oxidative and nitrosative stress (Wilkins et al., 2013).
Interestingly, a role for UCP2 in the transport of mGSH has
been described in neurons, suggesting that the transport of pro-
tons back into the matrix by UCP2 may favor the movement of
GSH (de Bilbao et al., 2004). These studies suggest that multiple
IMM anion transporters might be involved in mGSH transport
and that they might differ in different cell populations within the
brain. These ﬁndings indicate that mGSH levels and its transport
are major determinants in brain cell susceptibility to oxidative
stress, although little is known about the regulation of the mGSH
transport in brain.
MITOCHONDRIAL MEMBRANE PROPERTIES AND IMPACT ON
GLUTATHIONE IMPORT
Previous studies in liver mitochondria have revealed that mem-
brane dynamics regulate the transport of mGSH. Membrane
physical properties are mainly regulated by fatty acid composition
and the cholesterol/phospholipid molar ratio (Coll et al., 2003;
Lluis et al., 2003; Ikonen, 2008). Parallel to the ﬁndings from rat
liver mitochondria, it has been recently reported that mitochon-
drial cholesterol enrichment, resulting in mGSH depletion, is a
major mechanism of anthrax lethal toxin-induced macrophage
cell death (Ha et al., 2012). Mitochondria are cholesterol-poor
organelles compared to plasma membrane, and this regulated
transport of cholesterol in mitochondria plays physiological role
in the synthesis of bile acids in liver and steroidogenic hor-
mones in other tissues. (Garcia-Ruiz et al., 2009; Montero et al.,
2010). Consistent with the role of cholesterol in the regulation
of membrane dynamics, cholesterol loading in mitochondrial
membrane results in increased membrane order parameter and
in the reduction in the activity of speciﬁc membrane carriers,
i.e., GSH transport system without effect on other transporters,
indicating that the impact of changes in membrane dynamics
on carrier function is not universal (Fernandez et al., 2009a; Ha
et al., 2012). Moreover, functional expression studies in X. lae-
vis oocytes demonstrated that the OGC is sensitive to increased
membrane order caused by cholesterol loading (Coll et al., 2003).
Thus, cholesterol regulates the transport of mGSH, which in turn,
modulates susceptibility to oxidative stress and cell death, there-
fore emerging as an important target in pathophysiology of diverse
diseases such as steatohepatitis (SH) or Alzheimer’s disease (AD;
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Figure 4; Krahenbuhl et al., 1995; Armstrong and Jones, 2002;
Garcia-Ruiz et al., 2002; Fernandez-Checa and Kaplowitz, 2005;
Lluis et al., 2005, 2007; Mari et al., 2006, 2008, 2009; Lu and
Armstrong, 2007; Fernandez et al., 2009b; Fernandez-Checa et al.,
2010).
Based on the above ﬁndings, understanding the regulation
of mitochondrial cholesterol trafﬁcking may be of potential rel-
evance in cell death regulation and disease progression. Given
its lipophilic properties and water insolubility, non-vesicular
transport by speciﬁc carriers stands as the major mechanism
of cholesterol transport between organelles. In particular, mito-
chondrial cholesterol transport is preferentially regulated by the
steroidogenic acute regulatory domain 1 (StARD1), the founding
member of a family of lipid transporting proteins that con-
tain StAR-related lipid transfer (START) domains (Miller, 2013).
StARD1 is an OMM protein which was ﬁrst described and best
characterized in steroidogenic cells where it plays an essential role
in cholesterol transfer to the IMM for metabolism by cholesterol
side chain cleavage enzyme (CYP11A1) to generate pregnenolone,
the precursor of steroids. Pregnenolone synthesis in mitochon-
dria is limited by the availability of cholesterol in the IMM (Clark,
2012). Despite similar properties with StARD1, other StART
members cannot replace StARD1, as germline StARD1 deﬁciency
is lethal due to adrenocortical lipoid hyperplasia (Caron et al.,
1997). For instance, targeted mutations in MLN64 (StARD3),
another START member with wide tissue distribution, have been
shown to cause minor alterations in metabolism and intracel-
lular distribution of cholesterol, questioning its contribution to
intramitochondrial cholesterol trafﬁcking (Kishida et al., 2004;
Miller, 2007). StARD1 activation and regulation is complex and
poorly understood. Its activation is regulated at the transcrip-
tional and post-translational levels, as StARD1 phosphorylation
at serine194 has been shown to enhance the trafﬁcking of choles-
terol to IMM in murine steroidogenic cells, resulting in increased
steroidogenesis (Arakane et al., 1997; Kil et al., 2012). Moreover,
the role of ER stress in the regulation of StART family members
has been limited to StARD5 with conﬂicting results reported for
StARD4. However, recent data have provided evidence that ER
FIGURE 4 | Regulation of mGSH by mitochondrial cholesterol loading in
health and disease. (A) In healthy mitochondria, mGSH levels can cope with
the ROS generated in physiological conditions, avoiding cell death induction
and maintenance of mitochondrial functions. (B) In cholesterol-enriched
mitochondria, the mGSH transport is impaired resulting in mGSH depletion.
mGSH levels below a certain threshold compromise ROS detoxiﬁcation,
leading to oxidative stress and resulting ultimately in higher susceptibility to
cell death. (C) However, cancer cells exhibit increased cholesterol enrichment
of mitochondrial membrane but paradoxically maintain mGSH levels despite
changes in membrane physical properties by an as yet uncharacterized
mechanism. Increased mitochondrial cholesterol and mGSH protect against
mitochondrial membrane permeabilization and cell death. Thus, targeting
mitochondrial cholesterol or mGSH may be a novel approach in the treatment
of cancer.
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stress induces the transcriptional upregulation of StARD1 inde-
pendently of SREBP regulation (Fernandez et al., 2013). High
cholesterol feeding caused the repression of SREBP-2 regulated
genes, HMG-CoA reductase, but not that of StARD1. Similar
ﬁndings have been reported in brain mitochondria in a murine
model of AD (Barbero-Camps et al., 2014). Furthermore, the
increase in mitochondrial cholesterol in brain mitochondria of
AD was not accompanied by a selective increase in mitochondrial-
associated membranes (MAMs), corresponding to the contact
between ER and mitochondria, suggesting that StARD1-mediated
cholesterol trafﬁcking to mitochondria is independent of MAM,
a speciﬁc membrane domain made of ER and mitochondria
bilayers, which is thought to be of relevance in the trafﬁc of
lipids. TSPO, a protein particularly abundant in steroidogenic
tissues and primarily localized in the OMM, has been suggested
to play an important role in steroidogenesis via the transport of
cholesterol to the IMM (Papadopoulos and Miller, 2012; Miller,
2013). However, quite interestingly, recent studies using tissue-
speciﬁc genetic deletion of TSPO demonstrated that TSPO is
dispensable for steroidogenesis in Leydig cells (Morohaku et al.,
2014), questioning the relevance of previous ﬁndings on TSPO
using pharmacological ligands and inhibitors. These data under-
score that TSPO does not play a signiﬁcant role in the trafﬁcking
of cholesterol to IMM, and highlights the relevance of StARD1 in
this process.
Finally, a role for caveolin-1 (CAV1) in mitochondrial choles-
terol has been recently reported. CAV1 is a key component of
caveolae, specialized membrane domains particularly enriched
in cholesterol and sphingolipids, and CAV is known to bind
cholesterol with high afﬁnity (Murata et al., 1995; Pol et al., 2005;
Boscher and Nabi, 2012). CAV’s ability to move between cell
compartments, mitochondria–ER and plasma membrane, might
contribute to regulation of cholesterol ﬂuxes and distributions
within cells (Pol et al., 2001, 2005; Parton and Simons, 2007;
Bosch et al., 2011). In line with these features, CAV1 deﬁciency has
been shown to increase mitochondrial cholesterol in hepatocytes
causing perturbations in mitochondrial membrane dynamics and
function, and as expected, mGSH depletion (Bosch et al., 2011).
The mitochondrial dysfunction sensitizes CAV1 null mice to SH
and neurodegeneration. Whether the trafﬁcking of mitochon-
drial cholesterol in the absence of caveolin-1 occurs via MAM
or StARD1 remains to be further investigated.
ROLE OF MITOCHONDRIA AND MITOCHONDRIAL GSH IN
DISEASE
Given the role of mitochondria in oxygen consumption,
metabolism and cell death regulation, alterations in mitochon-
drial function or dysregulation in cell death pathways contribute
to many diseases such as cancer, SH, or neurodegeneration.
Consistent with its role in regulating mGSH, mitochondrial
cholesterol accumulation emerges as a key factor regulating ROS
and electrophile detoxiﬁcation, and hence disease progression by
sensitizing to secondary hits such as TNF,hypoxia or toxic amyloid
peptides. In the following sections we will brieﬂy cover examples
of diseases where mitochondria cholesterol, oxidative stress, and
mGSH depletion have been shown to play a role, such as cancer,
fatty liver disease, and AD.
CANCER BIOLOGY AND THERAPEUTICS
Cancer cells exhibit critical metabolic transformations induced
by mutations in oncogenes (gain-of-function) and tumor sup-
pressor genes (loss-of-function) that result in cell deregulation
associated with enhanced cellular stress. Adaptation to this stress
phenotype is required for cancer cells to survive and involves the
participation of genes that regulate generation and sensitization
to ROS-mediated cell death. In this context, small molecules
that selectively kill cancer cells are a promising approach for
the treatment of cancer. Experiments using a cell-based small-
molecule screening and quantitative proteomics, revealed the
potential of piperlongumine, a natural product isolated from
the plant species Piper longum L, as a cytotoxic agent triggering
apoptosis and necrosis in leukemia cells (Bezerra et al., 2007).
Moreover, piperlongumine induces ROS generation resulting in
the killing of transformed cells in vitro and in vivo but not pri-
mary normal cells (Raj et al., 2011). Piperlongumine leads to
decreased GSH and increased GSSG levels in cancer cells with-
out effects in non-transformed cells, and these effects paralleled
the ability of piperlongumine to cause alterations in mitochon-
drial morphology and function. Consequently, co-treatment
with piperlongumine and N-acetyl-L-cysteine (NAC) prevented
piperlongumine-mediated GSH depletion and cell death in can-
cer cells. These ﬁndings support the concept that normal cells
have low basal levels of ROS and a diminished reliance on the
ROS stress-response, while cancer cells have high levels of ROS,
and hence, are expected to have a strong reliance on the ROS
stress-response pathway. In linewith the relationship betweenROS
and cancer it has been suggested that antioxidants may protect
against cancer. However, randomized clinical trials have produced
inconsistent results and some studies indicated that antioxidants
increase cancer risk (van Zandwijk et al., 2000; Klein et al., 2011;
Watson, 2013). A recent study in oncogene-induced lung cancer
demonstrated that treatment with NAC and vitamin E accelerate
cancer progression, stimulating cell proliferation by reducingROS,
DNA damage, and p53 expression (Sayin et al., 2014). The use of
small molecules that alter the levels of ROS such as β-phenethyl
isothiocyanate (PEITC), buthionine sulphoximine, curcumin, or
2-cyano-3,12-dioxooleana-1,9-diene-28-oic acid (CDDO) deriva-
tives, has been suggested for the treatment of cancer by promoting
ROS generation and GSH depletion in cancer cells (Schumacker,
2006; Trachootham et al., 2006; Yue et al., 2006; Ravindran et al.,
2009). Interestingly,mGSHdepletionhas alsobeen associatedwith
apoptosis or autophagy induced by chemotherapeutic drugs. For
instance, the novel triterpenoidmethyl CDDOderivative (CDDO-
Me) potently induced cytotoxicity in imatinib-resistant myeloid
leukemia cells, accompanied by a rapid and selective depletion of
mGSH resulting in increased generation of ROS and mitochon-
drial dysfunction (Samudio et al., 2005, 2008). Moreover, PEITC
caused a rapid depletion of mGSH and a signiﬁcant elevation of
ROS and NO, induced a disruption of the mitochondrial electron
transport complex I, and a signiﬁcant suppression of mitochon-
drial respiration that resulted in cytotoxicity in leukemia cells
(Chen et al., 2011).
As mGSH is regulated by cholesterol, as described above, the
trafﬁcking of mitochondrial cholesterol may modulate cancer
cell biology. Cholesterol metabolism is deregulated in tumors,
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which exhibit a paradoxical stimulation in de novo cholesterol
synthesis despite hypoxia-mediated downregulation of HMG-
CoA reductase by hypoxia (Nguyen et al., 2007; Garcia-Ruiz
et al., 2009). In addition to its continued synthesis, choles-
terol trafﬁcking to mitochondria has been reported in tumor
cells, including in mitochondria from hepatocellular carcinoma
(HCC) due to overexpression of StARD1 (Montero et al., 2008).
Mitochondrial cholesterol loading in cancer cells may actu-
ally account for the recognized mitochondrial dysfunction and
resistance to Bax-mediated cell death induced by chemotherapy
agents. In line with this hypothesis, treatments that resulted
in mitochondrial cholesterol loading in tumor cells impaired
stress-induced apoptosis (Lucken-Ardjomande et al., 2008; Mon-
tero et al., 2008), while StARD1 knockdown or treatments that
resulted in downregulation of cholesterol loading sensitized HCC
cells to chemotherapy. These ﬁndings identify the mitochondrial
cholesterol loading in cancer cells, particularly HCC, as a mech-
anism contributing to chemotherapy resistance and evasion of
Bax-mediated apoptosis (Figure 4). While mitochondrial choles-
terol depletes mGSH due to impaired transport via OGC in
primary hepatocytes and in SH, cancer cells paradoxically main-
tain mGSH homeostasis by a still ill-deﬁned mechanism that is
under investigation.
ALCOHOLIC AND NON-ALCOHOLIC FATTY LIVER DISEASE
Fatty liver disease represents a spectrum of liver disorders that
begins with simple steatosis. This intial stage can progress to SH
and culminate in cirrhosis and liver cancer. SH is an interme-
diate stage of fatty liver disease and one of the most common
causes of chronic liver disease worldwide that may progress to
cirrhosis and liver cancer. SH is characterized by steatosis, oxida-
tive stress, hepatocellular death, inﬂammation and ﬁbrosis and
encompasses alcoholic (ASH) and non-alcoholic steatohepati-
tis (NASH). Unfortunately, there is no approved therapy for
ASH/NASH, which reﬂects our incomplete understanding of the
underlyingmechanisms (Tilg andDiehl, 2000; Angulo and Lindor,
2002; Brunt, 2004). The development of steatosis in ASH/NASH
is secondary to the metabolic disturbances in ASH and NASH,
including insulin resistance, adipose tissue lipolysis, stimulation
of de novo lipid synthesis and impaired mitochondrial fatty acid
oxidation (Garcia-Ruiz and Fernandez-Checa, 2006; Garcia-Ruiz
et al., 2011, 2013a,b). A key concept in SH pathogenesis is the
two-hit hypothesis, which posits that hepatic steatosis sensitizes
fatty liver to secondary hits, such as inﬂammatory cytokines
and oxidative stress. However, recent evidence has shown that
the type rather than the amount of fat plays a critical role in
the transition from steatosis to ASH/NASH. In line with this
hypothesis, previous studies have shown that chronic alcohol
feeding in various models results in the depletion of mGSH
due to cholesterol loading in mitochondria (Garcia-Ruiz et al.,
1994; Colell et al., 1997, 1998, 2001; Zhao et al., 2002; Garcia-
Ruiz and Fernandez-Checa, 2006) and that strategies aimed to
correct the loss of mitochondrial membrane ﬂuidity restore the
mitochondrial transport of GSH and replenish the mGSH pool
in alcohol-fed models. Moreover, recent evidence in rats fed an
ethanol-polyunsaturated fatty acid treatment conﬁrmed the mito-
chondrial cholesterol accumulation and GSH depletion, leading
to SH, and these effects were prevented by betaine treatment
(Varatharajalu et al., 2014). Altered alcohol-induced ER stress
involves alterations in the methionine cycle and hyperhomocys-
teinemia, and treatment with betaine prevents alcohol-induced
ER stress, steatosis, and liver injury (Ji and Kaplowitz, 2003,
2004). Moreover, tauroursodeoxycholic acid, a chemical chap-
erone shown to prevent ER stress (Ozcan et al., 2006), restored the
mGSH pool in alcohol fed rats (Colell et al., 2001) and blocked
alcohol-induced ER stress (Fernandez et al., 2013). The mecha-
nisms of alcohol-induced mitochondrial cholesterol trafﬁcking,
mediated by alcohol-induced upregulation of StARD1, requires
alcohol-induced acid sphingomyelinase activation (Fernandez
et al., 2013).
Increased cholesterol synthesis and levels have been reported in
liver biopsies frompatientswithNASH (Puri et al., 2007; Caballero
et al., 2009) and mGSH depletion has been observed in models
and patients with NASH (Serviddio et al., 2008). This outcome
is consistent with the increased expression of StARD1 in patients
with NASH but not with simple steatosis (Caballero et al., 2009).
In line with these ﬁndings, recent data reported that the inhi-
bition of microsomal triglyceride transfer protein, a model of
liver steatosis, induced the increase in free cholesterol in mito-
chondria resulting in mGSH depletion (Josekutty et al., 2013).
In addition to mGSH depletion, NASH is also characterized by
impaired SOD2 activity, which may contribute the increased gen-
eration of mitochondrial superoxide and subsequent peroxynitrite
levels that targetmitochondrial proteins causing their inactivation.
In principle, strategies such as SOD mimetics aimed to improve
SOD2 activity may be of relevance in NASH. However, the use of
SOD mimetics in parallel with the reported mGSH depletion can
cause increased H2O2 and overall oxidant-dependent liver injury
(Montfort et al., 2012). This scenario implies that the combination
of SOD mimetics and mGSH replenishment may more efﬁcient in
NASH treatment.
ALZHEIMER DISEASE
Alzheimer disease is a major neurodegenerative disorder and the
main cause of adult dementia. The main risk factor for AD
is aging and therefore the number of people worldwide facing
AD development increases every year. AD is characterized by
progressive memory loss, cognitive impairment and disruption
of synaptic plasticity. Although there are recommended ther-
apies for AD, such as acetylcholinesterase inhibitors and the
N-methyl-D-aspartate receptor antagonists, they are inefﬁcient
and do not prevent disease progression, reﬂecting our incom-
plete understanding of AD pathogenesis. Experimental models
and human data established two main theories underlying AD,
the accumulation of toxic amyloid β (Aβ) peptides, charac-
teristic of senile plaques, and the aggregation of tau protein,
a microtubule-associated protein expressed in neurons that is
involved in the stabilization of microtubules in the cytoskele-
ton. The pathogenic processing of the amyloid precursor protein
(APP) leads to toxic Aβ generation and is considered a criti-
cal mechanism of AD. Accordingly, a coding mutation (A673T)
in APP has been recently shown to protect against AD and
age-related cognitive decline in elderly Icelanders (Jonsson et al.,
2012). This substitution, which is close to the aspartyl protease
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β-site in APP, reduces the formation of amyloidogenic peptides
in vitro by 40%. The protective effect of the A673T substitu-
tion against AD provides strong evidence for the hypothesis that
reducing the β-cleavage of APP may protect against the disease.
Amiloidogenic processing of APP yields toxic Aβ peptides. In
this pathway, the β- and γ-secretases cleave APP at the N- and
C-termini of the Aβ peptide, respectively. β-Secretase has been
characterized as a membrane-bound aspartic protease termed
beta-site APP-cleaving enzyme 1 (BACE1), while γ-secretase is
a complex comprised of presenilin-1 or -2, nicastrin, anterior
pharynx-defective 1 (Aph-1) and presenilin enhancer 2 (Pen-2;
Haass, 2004). Another novel member of the γ-secretase com-
plex has been identiﬁed. β-arrestin 2 physically associates with
the Aph-1α subunit of the γ-secretase complex and redistributes
the complex toward detergent-resistant membranes, increasing
the catalytic activity of the complex (Thathiah et al., 2013). More-
over, β-arrestin 2 expression is elevated in individuals with
AD and its overexpression leads to an increase in Aβ pep-
tide generation, whereas genetic silencing of Arrb2 (encoding
β-arrestin 2) reduces generation of Aβ in cell cultures and in
Arrb2−/− mice. In addition to its amyloidogenic processing by
β- and γ-secretases, APP can be cleaved within the Aβ domain
by α-secretase. This non-amyloidogenic processing prevents the
deposition of intact Aβ peptide and results in the release of
a large soluble ectodomain, sAPPα, from the cell, which has
neuroprotective and memory-enhancing effects. Members of the
ADAMs, a disintegrin and metalloprotease family of proteases,
have been shown to possess α-secretase activity (Hooper and
Turner, 2002). The pathogenic processing of APP into toxic Aβ
fragments occurs in cholesterol-enriched membrane domains of
the plasma membrane, known as lipid rafts, consistent with the
recognized role of cholesterol in AD pathogenesis based upon
experimental and epidemiological evidence linking plasma choles-
terol levels and AD development (Notkola et al., 1998; Wolozin
et al., 2000; Anstey et al., 2008). High cholesterol levels corre-
lated with Aβ deposition and the risk of developing AD, while
patients taking the cholesterol-lowering drug statins were found
to have a lower incidence of the disease (Notkola et al., 1998;
Wolozin et al., 2000). Exploiting the relative detergent insolubility
of lipid rafts, there has been evidence indicating the localiza-
tion of APP, the α-, β- and γ-secretases in rafts (Wahrle et al.,
2002; Vetrivel et al., 2005). In addition, the activities of BACE1
and γ-secretase are stimulated by lipid components of rafts,
such as glycosphingolipids and cholesterol (Sawamura et al., 2004;
Kalvodova et al., 2005; Ariga et al., 2008; Osenkowski et al., 2008).
Besides its extracellular deposition, current evidence indicates the
processing and targeting of APP and Aβ to intracellular sites,
including mitochondria (Lin and Beal, 2006). Moreover, lev-
els of mitochondrial APP are higher in affected brain areas and
in subjects with advanced disease symptons (Devi et al., 2006).
Immunoelectron microscopy analyses indicated the association
of APP with mitochondrial protein translocation components,
TOM40 and TIM23, which correlated with decreased import
of respiratory chain subunits in vitro, decreased cytochrome
oxidase activity, increased ROS generation and impaired mito-
chondrial reducing capacity (Devi et al., 2006). Although the
molecular mechanisms of mitochondrial Aβ targeting remains
poorly understood, Aβ stimulates mitochondrial ROS genera-
tion, contributing to Aβ toxicity in neurons (Behl et al., 1994;
Casley et al., 2002; Lustbader et al., 2004). In addition to the
amyloidogenic effect of cholesterol by fostering Aβ generation
from APP, recent data has provided evidence that mitochondrial
cholesterol accumulation sensitizes neurons to Aβ-induced neu-
roinﬂammation and neurotoxicity by depleting mGSH, effects
that are prevented by mGSH replenishment (Fernandez et al.,
2009b). The mechanism of mitochondrial cholesterol accumu-
lation involves the upregulation of StARD1 induced by Aβ via
ER stress (Barbero-Camps et al., 2014), conﬁrming previous
ﬁndings in hepatocytes (Fernandez et al., 2013). Although not
reported in patients, the trafﬁcking of cholesterol to mitochon-
dria may be of clinical relevance to human AD due to the
described enhanced expression of StARD1 in pyramidal hip-
pocampal neurons of AD-affected patients (Webber et al., 2006).
Moreover, a novel mouse model engineered to have enhanced
cholesterol synthesis by SREBP-2 overexpression superimposed to
APP/PS1 mutations triggered Aβ accumulation and tau pathol-
ogy (Barbero-Camps et al., 2013). This triple transgenic model
exhibited increased mitochondrial cholesterol loading and mGSH
depletion and accelerated Aβ generation by β-secretase activation
compared to APP/PS1 mice (Barbero-Camps et al., 2013). More-
over, SREBP-2/APP/PS1 mice displayed synaptotoxicity, cognitive
decline, tau hyperphosphorylation and neuroﬁbrillary tangle for-
mation in the absence of mutated tau, indicating that cholesterol,
particularly mitochondrial cholesterol, can precipitate Aβ accu-
mulation and tau pathology. Importantly, in vivo replenishment
of mGSH with cell- permeable GSH monoethyl ester (GSH–EE)
attenuatedneuropathological features of AD in SREBP-2/APP/PS1
mice.
In addition to the proteolytic processing by secretases, APP
and its corresponding C-terminal fragments are also metabo-
lized by lysosomal proteases. SORLA/SORL1 is a unique neuronal
sorting receptor for APP that has been causally implicated in
sporadic and autosomal dominant familial AD. Brain concentra-
tions of SORLA are inversely correlated with Aβ in mouse models
and AD patients. Indeed, transgenic mice overexpressing SORLA
exhibit decreased Aβ concentrations in brain (Caglayan et al.,
2014). Mechanistically, Aβ binds to the amino-terminal VP10P
domain of SORLA and this binding is impaired by a familial AD
mutation in SORL1. Moreover, sphingosine-1-phosphate (S1P)
accumulation by S1P lyase deﬁciency has recently been shown
to impair lysosomal APP metabolism, resulting in increased Aβ
accumulation (Karaca et al., 2014). The intracellular accumulation
of S1P interferes with the maturation of cathepsin D and degra-
dation of Lamp2, suggesting a general impairment of lysosomal
function and autophagy. As sphingolipids have strong afﬁnity to
bind cholesterol (Slotte, 1999; Ridgway, 2000), it is conceivable
that increased lysosomal cholesterol may contribute to impaired
lysosomal Aβ degradation in the S1P lyase knockout mice. How-
ever, this aspect remains to be investigated, raising the question
of whether lysosomal cholesterol plays a role in lysosomal Aβ
degradation and hence has any relevance in AD. Quite intrigu-
ingly, recent ﬁndings have reported increased expression of the
lysosomal cholesterol transporter Niemann–Pick type C disease 1
(NPC1) in AD (Kagedal et al., 2010). NPC is an endolysosomal
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protein essential for the intracellular regulation of cholesterol and
its mutation and loss-of-function elicits the lysosomal storage dis-
ease NPC disease, characterized by the accumulation of lysosomal
cholesterol and sphingolipids. NPC1 expression was described
to be upregulated at both mRNA and protein levels in the hip-
pocampus and frontal cortex of AD patients compared to controls
subjects. However, no difference in NPC1 expression was detected
in the cerebellum, a brain region that is relatively spared in AD.
Moreover,murine NPC1 mRNA levels increased in the hippocam-
pus of 12-month-old APP/PS1 mice compared to wild-type mice.
These ﬁndings strongly suggest the lack of lysosomal cholesterol
accumulation in AD, and imply that lysosomal impairment and
subsequent contribution to decreased Aβ degradation in AD may
occur through mechanisms independent of cholesterol accumula-
tion in lysosomes. Although several similarities exist betweenNPC
disease and AD, including altered intracelular cholesterol home-
ostasis, changes in the lysosomal function, neuroﬁbrillary tangles,
and increased Aβ generation and neurodegeneration, the likely
common nexus between these diseases is mitochondrial choles-
terol loading, rather than lysosomal cholesterol accumulation,
as reported both in AD and NPC disease (Yu et al., 2005; Colell
et al., 2009; Fernandez et al., 2009b). Thus, targeting mitochon-
drial cholesterol may be of relevance not only for AD but also for
other neurodegenerative and lysosomal storage diseases, including
NPC.
CONCLUSION AND FUTURE APPROACHES
Mitochondria play an essential role in providing the energy needed
for multiple signaling cascades and cellular functions. The con-
sumption of molecular oxygen in the respiratory chain not only
is the driving force for the ATP synthesis required for cell via-
bility, but also the source of ROS that target mitochondrial and
extramitochondrial targets. As described above, mitochondrial
oxidative stress and the mGSH depletion are central events of
many pathological conditions. However, a challenge to coun-
teract mitochondrial oxidative stress is to recover mGSH pool
when GSH transport is defective due to alterations in membrane
dynamics triggered by increased mitochondrial cholesterol accu-
mulation. In addition to the ability of mitochondrial-permeable
GSH-EE to directly increasemGSH levels bypassing themitochon-
drial transport defect, it has been recently described additional
strategies that supply mitochondria with GSH, including parental
molecules that generate GSH once inside the mitochondrial
matrix. This approach has been recently illustrated with the use
of S-D-lactoylglutathione (Armeni et al., 2014). This compound
is an intermediate of the glyoxalase system, which is hydrolyzed
in the mitochondrial matrix yielding lactate and GSH; hence
showing the ability to replenish mGSH resulting in recovery of
mitochondrial function and antioxidant defense. Unlike these
permeable GSH prodrugs that directly boost mGSH, strategies
aimed to increase cytosol GSH (e.g., NAC) may not be an optimal
approach for boosting mGSH and therefore for treatment of SH
or AD, as it would result in mainly increasing cytosol GSH with-
out replenishing mGSH levels. Another strategy to combat ROS
generation would be the supply of antioxidants that are targeted
selectively to mitochondria. Since lipophilic cations accumulate
in mitochondria, the covalent attachment of a neutral bioactive
compound to a lipophilic cation should lead to its selective deliv-
ery to mitochondria. In this regard, alkyl-triphenylphosphonium
(TPP) cations are excellent tools for the delivery of compounds
to mitochondria as they preferentially accumulate quite efﬁciently
within mitochondria in cells, making it possible to deliver a wide
range of mitochondria-targeted lipophilic TPP-labeled cations
(Ross et al., 2005; Sheu et al., 2006). This approach has been
exploited recently in several contexts by the development of a
series of cationic antioxidants targeted to mitochondria, including
derivatives of the endogenous antioxidants ubiquinol (MitoQ),
alpha-tocopherol (MitoVit E), and of the synthetic spin trap
PBN (MitoPBN; Ross et al., 2005). These compounds have been
found to block oxidative damage in isolated mitochondria and
cells more effectively than untargeted antioxidant analogs due to
their concentration within mitochondria. More importantly, oral
administration of these compounds leads to their accumulation
in the brain, heart, muscle and liver mitochondria (Ross et al.,
2005). In fact, MitoQ has been used in a range of in vivo studies,
in rats and mice, and in two phase II human trials demonstrating
that it can be safely delivered to patients with promising results,
lending further support that mitochondria-targeted antioxidants
may be applicable to a wide range of human pathologies that
involve mitochondrial oxidative damage (Smith and Murphy,
2010).
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